Characterization of the Mammalian Initiation Factor eIF2B Complex as a GDP Dissociation Stimulator Protein*

Daniel D. WilliamsDagger §, Nigel T. Price||, A. Jane Loughlin**DaggerDagger, and Christopher G. ProudDagger **§§

From the Dagger  School of Life Sciences, Medical Sciences Institute/Wellcome Trust Biocentre Complex, University of Dundee, Dow Street, Dundee DD1 5EH, United Kingdom, the  Department of Biochemistry, University of Bristol, University Walk, Bristol BS8 1TD, United Kingdom, and the ** Research School of Biosciences, University of Kent at Canterbury, Canterbury CT2 7NJ, United Kingdom

Received for publication, December 29, 2001, and in revised form, April 24, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Initiation factor eIF2B mediates a key regulatory step in the initiation of mRNA translation, i.e. the regeneration of active eIF2·GTP complexes. It is composed of five subunits, alpha -epsilon . The largest of these (epsilon ) displays catalytic activity in the absence of the others. The catalytic mechanism of eIF2B and the functions of the other subunits remain to be clarified. Here we show that, when present at similar concentrations to eIF2, mammalian eIF2B can mediate release of eIF2-bound GDP even in the absence of free nucleotide, indicating that it acts as a GDP dissociation stimulator protein. Consistent with this, addition of GDP to purified eIF2·eIF2B complexes causes them to dissociate. The alternative sequential mechanism would require that eIF2Bepsilon itself bind GTP. However, we show that it is the beta -subunit of eIF2B that interacts with GTP. This indicates that binding of GTP to eIF2B is not an essential element of its mechanism. eIF2B preparations that lack the alpha -subunit display reduced activity compared with the holocomplex. Supplementation of such preparations with recombinant eIF2Balpha markedly enhances activity, indicating that eIF2Balpha is required for full activity of mammalian eIF2B.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Eukaryotic initiation factor (eIF)1 2B is a heteropentameric protein, which catalyzes a key step in translation initiation, i.e. the exchange of guanine nucleotides on initiation factor eIF2. eIF2 binds GTP and in this form can also interact with the initiator methionyl-tRNA (Met-tRNAi) to form the ternary complex eIF2·GTP·Met-tRNAi (1, 2). Such complexes can then bind to the 40 S ribosomal subunit to form pre-initiation complexes, bringing the Met-tRNAi into position to recognize the AUG start codon of the mRNA following ribosomal scanning. The eIF2-bound GTP molecule is then hydrolyzed to GDP and Pi in a process that requires a further factor, eIF5. The inactive eIF2·GDP complex is released from the ribosome. The rate of release of GDP from eIF2 is very slow under physiological conditions, and the exchange of bound GDP for GTP, to regenerate active eIF2·GTP, requires an additional factor, eIF2B. The activity of eIF2B plays a key role in regulating the initiation of translation and can be controlled in several ways. For example, phosphorylation of the alpha -subunit of eIF2 inhibits eIF2B and serves to inhibit translation under a range of stressful conditions (1). Conversely, eIF2B is activated by many stimuli, which stimulate protein synthesis, including insulin, and this appears to involve changes in the state of phosphorylation of the largest (epsilon ) subunit of eIF2B (3, 4). eIF2B has also been reported to be regulated, in vitro, by a number of allosteric modulators, including nicotinamide adenine nucleotides (5-9). Studies using photoactivatable nucleotide analogs suggested that eIF2B contains binding sites for GTP and ATP, although the functions of these sites are unclear.

eIF2B is an unusually complicated guanine nucleotide exchange factor (GEF), those acting on small G-proteins such as Ras, for example, being much smaller monomeric proteins. The reasons for this complexity and the roles of the five subunits are still not completely clear. A major step toward addressing these issues has been the cloning of cDNAs encoding subunits of eIF2B. This has now been achieved for several species, including yeast (see, e.g., Refs. 10 and 11), mammals (see, e.g., Refs. 12-16), and Drosophila (17). Studies for all three sources have shown that the epsilon -subunit alone can catalyze nucleotide exchange on eIF2 (17-19), although its activity is enhanced by the others (18-20). eIF2Bepsilon forms a catalytic subcomplex with eIF2Bgamma , with which it shares some sequence similarity. The other three subunits also display mutual sequence similarity and form a second subcomplex, which appears to have a regulatory function (19). There is some disagreement over the role of the alpha -subunit. This polypeptide is encoded by a non-essential gene in yeast (GCN3), although it is required for regulation of eIF2B by phosphorylation of eIF2alpha (21). Similarly, studies in which mammalian eIF2B polypeptides were expressed in insect cells concluded that eIF2Balpha was dispensable for activity (22). However, others have found that preparations of eIF2B lacking the alpha -subunit showed reduced activity in nucleotide exchange (23), implying that this component was required for full activity.

There is also disagreement over the catalytic mechanism of eIF2B; early studies supported the so-called "ping-pong" or substituted enzyme mechanism (Mechanism A in Fig. 1; Ref. 24), which is the one utilized by another GEF involved in mRNA translation, the bacterial elongation factor EF-Ts (25) and by factors that promote nucleotide exchange on other GTP-binding proteins (26-29). These factors act to stimulate the release of bound guanine nucleotide and are thus termed "GDP dissociation stimulator proteins" (GDS proteins, Ref. 29).Other studies have suggested that eIF2B may operate via the alternative sequential mechanism (Mechanism B in Fig. 1; Refs. 30 and 31).

Here we demonstrate that the properties of eIF2B match the operation of the ping-pong mechanism and suggest that eIF2B acts as a GDS protein. We also show that eIF2Bbeta contains a binding site for purine nucleotides and that eIF2Balpha is required for the full activity of mammalian eIF2B.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Chemicals and Biochemicals-- Chemicals and biochemicals were obtained from BDH-Merck (Poole, Dorset, United Kingdom (UK)) or Sigma Alrich (Gillingham, Dorset, UK), unless otherwise stated. [3H]GDP (10Ci/mmol), [gamma -32P]GTP (5000 Ci/mmol), and [gamma -32P]ATP (30 Ci/mmol) were from Amersham International. X-ray film was from Konica. Restriction enzymes were from Promega.

Purification of eIF2 and eIF2B-- These proteins were purified as described previously (8), but using HeLa cell cytoplasm as the starting material (from Computer Cell Culture Center, Seneffe, Belgium). The cytoplasmic fraction was subjected to ammonium sulfate fractionation, and the material precipitating between 30% and 60% saturation was subjected to ion exchange chromatography successively on Q-Sepharose, S-Sepharose, MonoQ, and MonoS (all from Pharmacia Nycomed).

Assay of eIF2B Activity-- eIF2B was assayed by its ability to promote the release of [3H]GDP from preformed eIF2·[3H]GDP complexes (8), except that time allowed for formation of the eIF2·[ 3H]GDP binary complexes was extended to 20 min. In some cases, assays were performed with modifications (e.g. in the absence of unlabeled nucleotide) as described in the figure legends.

UV Cross-linking-- UV cross-linking reactions were performed using a Stratalinker 1800 (Stratagene). Reactions were 10 µl and contained 20 mM Hepes/NaOH, pH 7.6, 100 mM KCl, 5 µl of eIF2B (2 pmol), either 2.5 µCi of [gamma -32P]GTP or 2.5 µCi of [gamma -32P]ATP (as indicated), and either 0.5 or 2.5 µM unlabeled nucleotide (also as indicated). Reactions were incubated at 30 °C for 5 min prior to exposure to UV radiation (1.2 J/cm2) for 20 min on ice. Samples were then subjected to SDS-PAGE, and gels were stained with Coomassie Brilliant Blue and dried prior to exposure to x-ray film. Control reactions were either incubated at 30 °C for 5 min and then on ice for 20 min without exposure to UV radiation, or incubated on ice only, as detailed in the figure legend.

Cloning and Expression of His-eIF2Balpha and His-eIF2Bbeta -- eIF2Balpha in pET15b was provided by Dr. J. K. Tyzack (a former member of the laboratory at Dundee and Canterbury), and eIF2Bbeta in pET11a was provided by Dr. B. Craddock (a former member of our laboratory at Bristol). The regions encoding the open reading frames for both subunits were excised (using NdeI and BamHI for eIF2Balpha and NdeI and XhoI for eIF2Bbeta ) and ligated into pET28c (Novagen). Vectors were then transformed into Escherichia coli (BL21 DE3 pLysS) and grown overnight in LB containing 100 µg/ml kanamycin. They were then diluted 10-fold and grown to an A600 of 0.6. Cultures were cooled on ice for 15 min, and expression was induced with 1 mM isopropylthio-beta -D-galactoside for 2.5 h. Cells were the harvested by centrifugation (3500 × g) and lysed in 5% glycerol, 500 mM KCl, 20 mM Tris/HCl, pH 7.6, 3 mM MgCl2, 5 mM beta -mercaptoethanol, 10 mM imidazole, 0.1% Triton X-100, 5 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 1 µg/ml protease inhibitors (leupeptin, pepstatin, aprotinin, and benzamidine) at -80 °C. Following lysis cells were defrosted and sonicated to shear any DNA present. Purification of proteins was performed using nickel-nitrilotriacetic acid-agarose (Qiagen).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Dependence of eIF2B on Free Nucleotide for Catalytic Guanine Nucleotide Exchange-- eIF2B was purified from HeLa cell extract using a slightly modified version of the method used earlier for its isolation from reticulocyte lysates (see "Materials and Methods"). This yielded protein displaying five polypeptides migrating on SDS-PAGE. These polypeptides displayed expected apparent molecular weights for subunits of mammalian eIF2B. This material was devoid of eIF2, as assessed by staining with Coomassie Brilliant Blue (Fig. 2A) and by the much more stringent criterion of Western blotting with a sensitive monoclonal antibody against eIF2alpha (Fig. 2B). Such preparations are highly active in catalyzing exchange of labeled GDP bound to eIF2 for unlabeled GTP (Fig. 2C).

We (8) and others (30, 31) have previously reported that eIF2B failed to catalyze the release of labeled GDP from eIF2·[3H]GDP complexes unless excess unlabeled GTP was present. In view of the aims of this study, it was important to show that this was also true for this preparation of eIF2B, which is indeed the case as shown in Fig. 2C; whereas rapid release of bound [3H]GDP was observed when unlabeled GTP was present, very little release was observed in the absence of added GTP. A small degree of release of [3H]GDP was seen when the higher concentration of eIF2B was used, and this effect is discussed in greater detail below. Two different models have been proposed to explain the catalytic mechanism of eIF2B. These are depicted in Fig. 1. Briefly, in the ping-pong or substituted enzyme model, the binding of eIF2B to eIF2·GDP complexes elicits the release of the GDP, allowing GTP to bind to eIF2 to form active eIF2·GTP complexes and resulting in the release of the eIF2B (Fig. 1A). In this model, eIF2B is acting as a GDS. Complexes between eIF2, GDP, and eIF2B presumably do form, but only transiently, decaying as the GDP is released to yield eIF2·eIF2B binary complexes. The second model (sequential, Fig. 1B) involves the formation of a "ternary complex" containing eIF2·GDP, eIF2B and GTP. The data showing a requirement for added guanine nucleotide in order to observe the release of bound GDP from eIF2 have been taken as support for the sequential mechanism (B in Fig. 1) (30, 31). However, consideration of the two mechanisms reveals that they are also entirely consistent with mechanism A. Indeed, such behavior is a prediction of this mechanism as displayed in Fig. 1A. eIF2B is included in the assays used by ourselves and others at catalytic rather than stoichiometric amounts; in the assays depicted in Fig. 2C, typically the ratio of eIF2:eIF2B is about 1000:1. Inspection of the mechanism shown in Fig. 1A shows that for eIF2B to act catalytically, it must be released from the intermediate eIF2·eIF2B complex and that this requires free nucleotide. Free nucleotide would act to regenerate eIF2B, thus allowing it to function as a catalyst and thus to mediate further release of labeled GDP from the eIF2·[3H]GDP complexes, which are the substrate for this reaction.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 1.   Proposed mechanisms for the eIF2B-mediated exchange of nucleotides on eIF2. A, ping-pong or substituted enzyme-mechanism; binding of eIF2B to eIF2·GDP brings about release of GDP. Subsequent binding of GTP to eIF2 leads to formation of active eIF2·GTP binary complexes and release of eIF2B, regenerating free eIF2B for further rounds of catalysis (dotted line). B, sequential mechanism; this involves formation of a ternary complex (eIF2·GDP·eIF2B·GTP) and subsequent release of GDP and active eIF2·GTP.


View larger version (53K):
[in this window]
[in a new window]
 
Fig. 2.   Characterization of purified human eIF2 and eIF2B. A, gel of purified eIF2 and eIF2B preparations to show relative concentrations of protein. Samples of purified eIF2 or eIF2B (as indicated) were applied at differing dilutions to an SDS-polyacrylamide gel, which was then stained with Coomassie Brilliant Blue and thoroughly destained. Shown are the regions corresponding to eIF2alpha and eIF2Bbeta . We chose to use these polypeptides for comparative purposes as they possess almost identical molecular masses. B, purified eIF2 and eIF2B were diluted as indicated and 10 µl were analyzed by SDS-PAGE, followed by Western blotting using antisera to eIF2alpha and eIF2Balpha . The positions of these proteins on the resulting immunoblot are indicated. C, binary eIF2·[3H]GDP complexes were formed using fraction and gel-filtered over Sephadex G-50 to remove free labeled nucleotide. Complexes (4 pmol) were then incubated with no further addition, or with eIF2B (75 or 750 fmol, as indicated) and, where indicated, GTP/MgCl2 (to give final concentrations of 0.5 and 1.5 mM, respectively). Reaction mixtures (total volume, 60 µl) were incubated at 30 °C. At the times indicated, samples were removed and filtered through nitrocellulose membranes. Residual [3H]GDP binding was determined by scintillation spectrometry. Zero time values were obtained by processing samples of the binary complex, which had not been incubated with eIF2B or GTP/MgCl2. D, Coomassie-stained gel of the purified eIF2B used in these experiments; positions of its five subunits are indicated.

Since eIF2 can bind either GDP or GTP, one would expect that, under this model, catalytic exchange would proceed with either free GTP or GDP present. This is indeed the case for mammalian eIF2B (Fig. 2C and data not shown), as reported earlier for the yeast factor (11). Consistent with the earlier findings of Cigan et al. (11) for yeast eIF2B, ATP did not facilitate release of bound GDP from eIF2 (data not shown).

Guanine Nucleotides Cause Dissociation of eIF2·eIF2B Complexes-- A prediction of mechanism A, the ping-pong mechanism, but not of mechanism B, is that incubation of eIF2·eIF2B complexes with guanine nucleotides should cause such complexes to dissociate. The eIF2·eIF2B complex was purified by ion-exchange chromatography on MonoQ (Fig. 3A) and then incubated with GDP, followed by addition of MgCl2 and re-chromatography on MonoQ. During this second run, eIF2 was resolved from eIF2B (which eluted later from the column; see also Ref. 8 and Fig. 3 (B and C)). Chromatography of complexes that had not been pre-treated with GDP did not result in separation of the two proteins, which instead again eluted as the eIF2·eIF2B complex (data not shown). To study this further, we performed similar experiments using gel permeation chromatography rather than ion exchange to resolve eIF2 or eIF2B from eIF2·eIF2B complexes. When eIF2·eIF2B complexes were applied to a Superose 6 column without GDP treatment, as expected, eIF2 and eIF2B eluted together (Fig. 3D). In contrast, when another sample of the eIF2·eIF2B complexes was incubated with GDP and then applied to a Superose 6 column, eIF2 (seen in fractions 27-29) clearly eluted later than eIF2B (mainly in fractions 24-26), indicating that eIF2 and eIF2B had dissociated from one another (Fig. 3E). These data are again consistent with mechanism A, but not mechanism B, and support the contention that the ability of free GDP or GTP to facilitate the release of [3H]GDP bound to eIF2 is due to the regeneration of free, active eIF2B. The data again support the idea that eIF2B acts as a GDS.


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 3.   Addition of GDP causes dissociation of eIF2·eIF2B complexes. eIF2·eIF2B complexes were isolated as described under "Materials and Methods." A, Western blot of consecutive fractions from MonoS containing eIF2/eIF2B complexes as demonstrated using antisera for eIF2alpha and eIF2Bgamma (positions shown). B, a Coomassie-stained gel of the complex is shown (eIF2/eIF2B). GDP (final concentration 200 µM) was added to the complex (in Buffer A: 20 mM HEPES-KOH, pH 7.4, 100 mM KCl, 5% (v/v) glycerol, 1 mM dithiothreitol), and this was incubated for 30 min at 30 °C. MgCl2 was then added (final concentration, 5 mM), and the material was applied to a MonoQ column attached to a fast protein liquid chromatography system equilibrated in the same buffer supplemented with GDP (1 µM) and MgCl2 (5 mM). The column was developed with a salt gradient (KCl), and fractions were collected. Selected fractions were analyzed by SDS-PAGE followed by Coomassie staining or immunoblotting (shown in panel C). Fractions 20 and 29 correspond to KCl concentrations of 250 and 350 mM, respectively. In panel B, the migration positions of the subunits of eIF2 (alpha -gamma ) and eIF2B (alpha -epsilon ) are shown. The single bands in lanes 23-26 are contaminating proteins resolved on the MonoQ column and are not subunits of eIF2 or eIF2B. Vertical lines indicate separate gels, which have been combined for presentation. It should be noted that eIF2Balpha stains relatively weakly with Coomassie Blue when compared with the other subunits of the complex. C, this panel shows immunoblots developed with antisera against eIF2Bgamma or eIF2alpha as indicated. Note that, on the immunoblot for eIF2beta gamma , the peak fraction (28) was loaded at one-tenth the amount of the others. The last lane in each case shows the signal from the initial eIF2·eIF2B complex run in parallel. eIF2 is eluted at 240-260 mM KCl, whereas eIF2B, free of eIF2, was eluted between 335 and 350 mM KCl. When a sample of eIF2·eIF2B was subjected to ion exchange on MonoQ without prior treatment with GDP, and without GDP in the buffer, as a control, it was eluted at ~290-315 mM KCl as the complex, and no separation of eIF2 from eIF2B was observed (data not shown). D, purified eIF2·eIF2B complexes were applied to a Superose 6 column equilibrated in Buffer A containing 5 mM MgCl2. Fractions were collected, and the figure shows a Coomassie Blue-stained gel of those containing eIF2 and eIF2B. E, a second sample of the same material was preincubated with GDP (1 µM) for 15 min on ice prior to addition of MgCl2 (to 5 mM) and application to the same column now equilibrated in Buffer A with 5 mM MgCl2 and 1 µM GDP. Again, a Coomassie-stained SDS-polyacrylamide gel is shown. The migration positions of the subunits of eIF2 and eIF2B are indicated by labeled arrows. Similar data, showing separation of eIF2 from eIF2B in the presence of GDP but not in its absence, were obtained in four independent experiments.

Stoichiometric Amounts of eIF2B Can Mediate Nucleotide Release in the Absence of Free Nucleotide-- An additional prediction of mechanism A is that stoichiometric amounts of eIF2B should lead to extensive release of GDP even in the absence of free nucleotide. That this might be the case was suggested by the modest release of [3H]GDP observed in Fig. 2C in the presence of the higher amount of eIF2B. To test this further, eIF2·[3H]GDP complexes were formed and subjected to gel filtration to remove free nucleotide. Purified eIF2B was then added in increasing amounts similar to or greater than the amount of eIF2·[3H]GDP complexes present. Under these conditions, release of labeled GDP was observed (Fig. 4A). Release was not complete, but in each case leveled out at a maximum extent (as the reaction attained equilibrium). As expected, the extent of release increased as larger amounts of eIF2B were used, since this will drive the equilibrium further toward completion. This is precisely the behavior predicted from the ping-pong mechanism, where eIF2B can bring about the release of amounts of GDP similar to the amount of eIF2B added, but cannot act catalytically as it becomes locked into the eIF2·eIF2B complexes. The release of eIF2B from these complexes requires free GDP or GTP, enabling the eIF2B now to act catalytically rather than stoichiometrically. Consistent with this, upon addition of free nucleotide, rapid complete loss of bound labeled GDP occurred, due to the catalytic action of the eIF2B (Fig. 4B).


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 4.   eIF2B can mediate release of GDP from eIF2 in the absence of free nucleotide. A, eIF2·[3H]GDP complexes were formed and subjected to gel filtration to remove free GDP. Reaction mixtures (60 µl) contained 3 pmol of eIF2·[3H]GDP complexes and were incubated at 30 °C with no added eIF2B (control) or 1, 2.5, or 5 pmol eIF2B as indicated. GTP (0.5 mM final concentration, plus same concentration of MgCl2) was added to one reaction as indicated. Samples were removed at the times shown and processed to determine the [3H]GDP remaining associated with the eIF2. Zero time values are for eIF2·[3H]GDP complexes that had not been incubated. B, as panel A but using 4.5 pmol of eIF2·[3H]GDP/incubation and different amounts of eIF2B, as indicated. GTP was added after 20 min of incubation to a final concentration of 0.5 mM for another 10 min, and a final sample was taken.

Cross-linking of Purine Nucleotides to eIF2Bbeta -- Mechanism B requires that eIF2B contains a binding site for GTP and two earlier reports (for eIF2B from mammals (30) and yeast (31), respectively, have provided data indicating that eIF2B can bind GTP, albeit only to a low stoichiometry (~0.2 mol of GTP/mol of eIF2B). Since eIF2Bepsilon displays nucleotide exchange activity when expressed alone (17-19), one would expect that, if mechanism B were the mechanism of action of eIF2B, eIF2Bepsilon should possess a binding site for GTP. However, we were unable to observe any significant binding of [gamma -32P]GTP to our purified preparations of eIF2B complex in filter binding assays (binding <10% of the level seen for eIF2 on a molar basis; data not shown). Nevertheless, we pursued this issue further by using UV irradiation to cross-link [gamma -32P]GTP to purified eIF2B. (This material is free of eIF2, thus obviating the problem of GTP binding to any eIF2 present.) We elected to perform these studies using unmodified GTP rather than 8-azido-GTP (where the photoactivatable label is in the base), as used previously (32), since use of nucleotide analogs can give misleading results due to cross-linking to adjacent subunits in a protein complex rather than to the subunit which actually binds the nucleotide. An excellent example of this is eIF2 itself, where 8-azido-GTP (32) or other GTP analogs label eIF2alpha or -beta (33, 34) rather than, or as well as, eIF2gamma , the subunit that actually contains the GTP-binding site (35, 36). It could therefore be that the earlier studies, where 8-azido-GTP was cross-linked to eIF2Bbeta , rather than eIF2Bepsilon as expected for mechanism B, were also misleading. Our cross-linking studies using [gamma -32P]GTP resulted in labeling of a polypeptide migrating at ~40 kDa, i.e. in the position of eIF2Bbeta (Fig. 5A), confirming the earlier study of Haley et al. (32), who found that this polypeptide was also labeled by azido-GTP. However, in contrast to that study, labeling was reduced by the presence of cold ATP as well as by cold GTP (Fig. 5A). Similar labeling experiments using [gamma -32P]ATP led to labeling of the same polypeptide, rather than eIF2Bgamma and -delta reported by Haley et al. (32). To rule out the possibility that labeling occurred by transfer of the gamma -phosphate (e.g. by a contaminating kinase), reactions were also performed without UV irradiation. Under this condition, no labeling was indeed observed (Fig. 5B, lane 2). Labeling was decreased by addition of cold GTP or ATP (Fig. 5C), GTP being slightly more effective than ATP. This suggests that ATP and GTP bind to the same (or overlapping) sites in eIF2beta .


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 5.   Ultraviolet cross-linking of eIF2B to nucleoside triphosphates. A, cross-linking with [gamma -32P]GTP with competitors. eIF2B (0.5 pmol) was incubated with [gamma -32P]GTP as described under "Materials and Methods." Unlabeled nucleotides were included in the reactions at either 2.5 µM or 0.5 µM as indicated. None indicates that no unlabeled nucleotide was added. Samples were analyzed by SDS-PAGE and autoradiography. The figure shows an autoradiograph. The position of migration of eIF2Bbeta is marked by a labeled arrow. B, samples of eIF2B complex were subjected to UV cross-linking with [gamma -32P]GTP (lane 1), incubated in the same manner except without exposure to UV radiation (lane 2), or denatured immediately after addition of [gamma -32P]GTP (lane 3), followed by SDS-PAGE. The figure is an autoradiograph of the dried gel. The position of eIF2Bbeta is indicated. C, as panel A but [gamma -32P]ATP was employed in place of [gamma -32P]GTP. D, His-eIF2Bbeta was expressed in E. coli and purified as described under "Materials and Methods." Lane 1 shows a Coomassie-stained gel of the eIF2Bbeta obtained. Lanes 2-4 show results of experiments in which samples of His-eIF2Bbeta were subjected to UV cross-linking with [gamma -32P]GTP (lane 2), incubated in the same manner except without exposure to UV radiation (lane 3), or incubated on ice only (lane 4) followed by SDS-PAGE. The figure is an autoradiograph of the dried gel. The position of the His-eIF2Bbeta is indicated.

To verify that GTP bound directly to eIF2Bbeta , we expressed this polypeptide in E. coli as a His-tagged protein, purified it on nickel-agarose, and tested whether [gamma -32P]GTP became cross-linked to it. As shown in Fig. 5D (lane 2), UV irradiation did indeed result in cross-linking of labeled GTP to recombinant eIF2Bbeta . This confirms that GTP interacts directly with this subunit and thus that the cross-linking to this polypeptide observed for the complex is not a consequence of its binding to another subunit at a site adjacent to eIF2Bbeta in the holoprotein. As a negative control, reactions were again performed in the same way but without UV irradiation. In this case, no cross-linking was observed, once more ruling out the theoretical possibility that labeling by [gamma -32P]GTP was due to phosphorylation of eIF2Bbeta by a contaminating kinase (Fig. 5D, lanes 3 and 4).

eIF2B is also known to interact with NAD+ and related compounds (5, 8). To examine whether the binding site for these compounds was also located in eIF2Bbeta , we performed UV cross-linking experiments with radioactive NAD+. However, this failed to result in labeling of any of the polypeptides of eIF2B, although lactate dehydrogenase, used as a positive control, was labeled (data not shown). In another approach, we examined whether NAD+ or NADPH competed with GTP or ATP in the UV cross-linking experiments (Fig. 5). It did not; in fact, a reproducible increase in cross-linking was observed. It therefore appears that the nucleotide-binding site in eIF2Bbeta is not the site responsible for binding NAD+, which presumably resides elsewhere in the protein. The ability of NAD+ to enhance labeling by [gamma -32P]GTP or ATP may reflect allosteric interactions between the binding sites for these ligands.

eIF2Balpha Is Required for Full Activity of Mammalian eIF2B-- As reported previously (23), isolation of mammalian eIF2B from rabbit reticulocytes yields a proportion of the protein as a four-subunit complex lacking the alpha -subunit. The same is true of eIF2B prepared from HeLa cells (Fig. 6A). Chromatography on MonoS yielded two pools of eIF2B; the material eluting at 290-320 mM KCl showed only four subunits on SDS-PAGE (Fig. 6, A and B), whereas the material eluting at 330-370 mM showed five. The absence of eIF2Balpha from the former material was confirmed using an antibody specific for the alpha -subunit of eIF2B (Fig. 6A). No signal for eIF2Balpha was observed in these fractions, whereas a clear signal was seen for the factor displaying all five subunits on SDS-PAGE (Fig. 6B). When the activities of the four- and five-subunit preparations were compared, the former was found to display only about 20-25% of the activity of the five-subunit material in the standard nucleotide exchange assay (Fig. 6C). This is consistent with our earlier data for the four- and five-subunit preparations of the factor from rabbit reticulocytes (23). To confirm that the absence of eIF2Balpha from the four-subunit material was the explanation of its low activity, mammalian eIF2Balpha (rat) was expressed in E. coli (as a His-tagged polypeptide) and purified. This yielded material showing a single protein band on SDS-PAGE (Fig. 6C) that displayed no nucleotide exchange activity on its own (Fig. 6C). Supplementation of four-subunit eIF2B with recombinant rat eIF2Balpha markedly stimulated its activity, almost to the levels observed for the five-subunit protein (Fig. 6C). Thus, the deficiency in activity of eIF2Bbeta gamma delta epsilon relative to the heteropentamer does indeed appear to be due to lack of the alpha -subunit rather than any other defect.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 6.   The activity eIF2B lacking the alpha -subunit is enhanced by adding recombinant eIF2Balpha . A, immunoblots of purified eIFB lacking the alpha -subunit (lane 1), five-subunit eIF2B (lane 2), and eIF2/eIF2B complex probed with the anti-eIF2Bepsilon and -eIF2Balpha antisera. B, Coomassie-stained gel of the samples shown in A; eIF2 is also included (lane 4). C, guanine nucleotide exchange assay showing the activity of four subunit eIF2B, the activity of the four subunit eIF2B following a pre-incubation of 10 min at 30 °C with recombinant rabbit His-tagged eIF2Balpha and the activity of five subunit eIF2B. Also shown is an immunoblot of the recombinant His-eIF2Balpha using the anti-His antisera (inset). (Data show S.E. where n = 3.)


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The data presented here show that eIF2B can elicit release of [3H]GDP from eIF2 even in the absence of GDP or GTP. This apparently contradicts earlier data from ourselves (8) and (1, 30) others; however, these earlier experiments were mostly performed using catalytic amounts of eIF2B (i.e. low amounts compared with the substrate eIF2·[3H]GDP). We have reported previously that approximately stoichiometric amounts of eIF2B prepared from a different source did not elicit release of bound GDP from eIF2; in fact, the present data show that a roughly equal amount of eIF2B displaces approximately 50% of the nucleotide bound to eIF2. The extent release of bound GDP at any given ratio of eIF2B to eIF2 depends of course on the rate constants for the reaction eIF2·GDP + eIF2B left-right-harpoons  eIF2·eIF2B + GDP. The ping-pong mechanism does indeed predict that the catalytic function of eIF2B requires free nucleotide in order to regenerate eIF2B from the eIF2·eIF2B complexes, which are an intermediate in this mechanism (Fig. 1A). When added at stoichiometric amounts, as in this study, this mechanism predicts that GDP will be released from eIF2, as eIF2B displaces the nucleotide from eIF2. In complete accordance with this, we show that the addition of GDP to eIF2·eIF2B complexes causes them to dissociate, again as expected from the ping-pong mechanism. Neither of these effects is consistent with the other mechanism proposed for eIF2B (sequential mechanism, Fig. 1B). In our study we also failed to detect eIF2B bound to eIF2·GDP, an intermediate that may be formed in the substituted enzyme mechanism, but that cannot arise in the ping-pong mechanism. Thus, our data are in agreement with the ping-pong mechanism but do not, of course, prove that this is the mechanism by which eIF2B functions. Another GEF involved in translation, EF-Ts, also uses the substituted enzyme mechanism (25). RCC1 and Cdc25Mm, exchange factors for the small GTP-binding proteins Ran and Ras, respectively, have been shown to operate by an analogous mechanism (26-28), and recent data support such a mechanism for the guanine nucleotide dissociation factor that acts on Rho (29). It seems plausible that the substituted enzyme mechanism is a general one by which such proteins function, although the fine details of the mechanism at the structural level are likely to vary (37, 38). The data in Figs. 2 and 6 suggest that eIF2B acts as a GDS (by promoting the release of GDP from eIF2 rather than the exchange of GDP for GTP; GTP binds spontaneously to the unliganded eIF2).

Other studies have provided evidence that eIF2B can bind guanine nucleotides, which is a requirement of the substituted enzyme mechanism. Wahba and colleagues (30) reported GTP binding to mammalian eIF2B, although the stoichiometry was low. Similarly, recent data from Hannig's group (31) for yeast eIF2B show only a stoichiometry of only 0.2 mol/mol, even at a nucleotide concentration almost 3 orders of magnitude above the apparent dissociation constant. In this work we were unable to detect significant binding of GTP to purified eIF2B in filter binding assays. In addition, eIF2B does not bind to GDP-agarose (data not shown), although this could reflect steric problems due either to the means of attachment of the GDP to the resin (via the ribose hydroxyls) or to the large size of the eIF2B complex. It is possible that either the off-rates for guanine nucleotides are very high, despite the low apparent Kd reported by others, so that little or no stable binding is obtained, or that the low stoichiometry of binding seen by others reflects the presence of a contaminating nucleotide-binding protein, although none was evident on the gels shown by earlier workers (1, 30). We do nonetheless observe cross-linking of GTP to eIF2B, specifically to eIF2Bbeta . This suggests that the protein does indeed bind guanine nucleotides and that this subunit is involved in the interaction, as concluded by the earlier studies of Haley et al. (32), who used a photoaffinity-labeling reagent (8-azido-GTP) rather than normal GTP as used here. In our study, cross-linking of [gamma -32P]GTP was competed by ATP, and, consistent with this, [gamma -32P]ATP also became cross-linked to this subunit. These findings differ from the earlier results (32) where labeling by GTP was not affected by ATP, and where 8-azido-ATP became cross-linked to the gamma  and delta  subunits. It is not clear how this discrepancy is to be explained. Our data suggest that the binding site in eIF2Bbeta interacts with both ATP and GTP. The observation that the isolated recombinant beta -subunit is also labeled by [gamma -32P]GTP strongly supports the idea that this subunit directly binds guanine nucleotides, and that its labeling is not merely a consequence of the binding of GTP to an adjacent subunit in the complex. Since the sequence of eIF2Bbeta contains no identifiable nucleotide-binding motifs, its interaction with GTP and ATP must involve a non-canonical binding site.

We found that addition of NAD+ did not reduce the labeling of eIF2Bbeta by GTP or ATP, indicating that the binding site in eIF2Bbeta is distinct from that through which nicotinamide adenine dinucleotides exert their allosteric effects upon eIF2B activity. We were unable to achieve labeling of eIF2B using radiolabeled NAD+ and were thus also unable to try to locate the binding site in eIF2B for this nucleotide.

As noted above, the substituted enzyme mechanism requires that eIF2B possesses a binding site for GTP. Although our data suggest that there may be such a site, it is important to note that this resides in eIF2Bbeta , and not in the catalytic epsilon -subunit. This is a key point, since if eIF2B utilized the substituted enzyme mechanism, this site would necessarily be present in eIF2Bepsilon , which has been shown to catalyze nucleotide exchange on its own, based on data from three different groups for the protein from yeast, insects, and mammals (17-19). These findings thus also argue against the substituted enzyme mechanism. Taken together, the present data suggest that eIF2B mediates release of GDP from eIF2, allowing the subsequent binding of GTP (the more abundant of these two nucleotides in the cell). If this is the case, then eIF2B acts as a GDS protein rather than a nucleotide exchange factor (a name which could be taken to imply catalysis of the GDP/GTP exchange step itself). The physiological role of eIF2B is of course to promote this exchange process, but our data suggest that this is a consequence of its ability to bring about the release of GDP from eIF2, with binding of GTP occurring to the resulting nucleotide-free eIF2.

It has previously been suggested that purine nucleotides might act as allosteric modulators of eIF2B (39). Indeed, Kimball and Jefferson (9) have shown that ATP inhibits the activity of eIF2B. This effect is surprising in physiological terms, as one might expect enhanced cellular energy status, if anything, to activate eIF2B rather than inhibit it. Their data suggested that the effect might be mediated by antagonizing the activating effect of NADPH (9), which, based on our findings, is presumably mediated by a different binding site in eIF2B (since NAD+ did not reduce the labeling of eIF2Bbeta by GTP). The function of nucleotide binding to eIF2Bbeta therefore remains unclear.

A third area of conflicting data relating to eIF2B is the role of its smallest 32 (alpha ) subunit. Earlier studies agree that this subunit is required for the regulation of eIF2B activity by phosphorylation of eIF2alpha (22, 40, 41). However, genetic analysis in yeast or expression of mammalian eIF2B subunits in insect cells suggested that eIF2Balpha was not required for activity in vivo or in vitro, respectively. In contrast, our data for preparations of eIF2B that lack this subunit indicated it was necessary for full activity (23). The findings reported here confirm this for eIF2B isolated from a different source (HeLa cells versus reticulocyte lysate) and, most importantly, demonstrate that addition of recombinant eIF2Balpha almost completely restores eIF2B activity. This eliminates the possibility that the low activity of four-subunit eIF2B is due to other defects in the protein and demonstrates that, under in vitro assay conditions, the mammalian factor does require eIF2Balpha for full activity. Possible explanations for the differences between our data and those of earlier studies include (i) for the yeast studies, complementation of GCN3 by the product of another gene, or differences between the function of eIF2B in vitro and in vivo and (ii) for the studies in Spodoptera cells, the presence of endogenous insect eIF2Balpha in the complexes containing the four subunits of eIF2B from mammals, although no band is apparent at this position in the authors' SDS-polyacrylamide gels.

    ACKNOWLEDGEMENTS

We are grateful to Linda Campbell and Dr. Xuemin Wang for valuable assistance with the preparation of initiation factors.

    FOOTNOTES

* This work was supported by a committee studentship (to D. D. W.) and a project grant from the Biotechnology and Biological Sciences Research Council (to C. G. P.) and by Project Grant 037005 and Program Grant 046110 from the Wellcome Trust (to C. G. P.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Present address: Avidex Ltd., 57c Milton Park, Abingdon OX14 4RX, United Kingdom.

|| Present address: Dept. of Cell Biochemistry, Hannah Research Inst., Ayr, Scotland KA6 5HL, United Kingdom.

Dagger Dagger Present address: Dept. of Biological Sciences, Open University, Walton Hall, Milton Keynes MK7 6AA, United Kingdom.

§§ To whom correspondence should be addressed: Div. of Molecular Physiology, School of Life Sciences, Medical Sciences Institute/Wellcome Trust Biocentre Complex, University of Dundee, Dow St., Dundee DD1 5EH, Scotland, United Kingdom. Tel.: 44-1382-344919; Fax: 44-1382-322424; E-mail: c.g.proud@dundee.ac.uk.

Published, JBC Papers in Press, April 25, 2001, DOI 10.1074/jbc.M011788200

    ABBREVIATIONS

The abbreviations used are: eIF, eukaryotic initiation factor; GDS, guanine nucleotide dissociation stimulator; GEF, guanine nucleotide exchange factor; Met-tRNAi, initiator methionyl-tRNA; PAGE, polyacrylamide gel electrophoresis.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Hinnebusch, A. G. (2000) in Translational Control of Gene Expression (Sonenberg, N. , Hershey, J. W. B. , and Mathews, M. B., eds) , pp. 185-243, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
2. Webb, B. L. J., and Proud, C. G. (1998) Int. J. Biochem. Cell Biol. 29, 1127-1131[CrossRef]
3. Welsh, G. I., Miller, C. M., Loughlin, A. J., Price, N. T., and Proud, C. G. (1998) FEBS Lett. 421, 125-130[CrossRef][Medline] [Order article via Infotrieve]
4. Dholakia, J. N., and Wahba, A. J. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 51-54[Abstract]
5. Dholakia, J. N., Mueser, T. C., Woodley, C. L., Parkhurst, L. J., and Wahba, A. J. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 6746-6750[Abstract]
6. Singh, L. P., and Wahba, A. J. (1998) Biochem. Biophys. Res. Commun. 217, 616-623[CrossRef]
7. Singh, L. P., Aroor, A. R., and Wahba, A. J. (1995) Biochem. Biophys. Res. Commun. 212, 1007-1014[CrossRef][Medline] [Order article via Infotrieve]
8. Oldfield, S., and Proud, C. G. (1992) Eur. J. Biochem. 208, 73-81[Abstract]
9. Kimball, S. R., and Jefferson, L. S. (1995) Biochem. Biophys. Res. Commun. 212, 1074-1081[CrossRef][Medline] [Order article via Infotrieve]
10. Bushman, J. L., Foiani, M., Cigan, A. M., Paddon, C. J., and Hinnebusch, A. G. (1993) Mol. Cell. Biol. 13, 4618-4631[Abstract]
11. Cigan, A. M., Bushman, J. L., Boal, T. R., and Hinnebusch, A. G. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 5350-5354[Abstract]
12. Flowers, K. M., Kimball, S. R., Feldhoff, R. C., Hinnebusch, A. G., and Jefferson, L. S. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 4274-4278[Abstract]
13. Flowers, K. M., Mellor, H., Matts, R., Kimball, S. R., and Jefferson, L. S. (1996) Biochim. Biophys. Acta 1317, 318-324
14. Price, N. T., Kimball, S. R., Jefferson, L. S., and Proud, C. G. (1996) Biochem. J. 318, 631-636[Medline] [Order article via Infotrieve]
15. Craddock, B. L., Price, N. T., and Proud, C. G. (1995) Biochem. J. 309, 1009-1014[Medline] [Order article via Infotrieve]
16. Price, N. T., Mellor, H., Craddock, B. L., Flowers, K. M., Kimball, S. R., Wilmer, T., Jefferson, L. S., and Proud, C. G. (1996) Biochem. J. 318, 637-643[Medline] [Order article via Infotrieve]
17. Williams, D. D., Pavitt, G. D., and Proud, C. G. (2001) J. Biol. Chem. 276, 3733-3742[Abstract/Free Full Text]
18. Fabian, J. R., Kimball, S. R., Heinzinger, N. K., and Jefferson, L. S. (1997) J. Biol. Chem. 272, 12359-12365[Abstract/Free Full Text]
19. Pavitt, G. D., Ramaiah, K. V. A., Kimball, S. R., and Hinnebusch, A. G. (1998) Genes Dev. 12, 514-526[Abstract/Free Full Text]
20. Gomez, E., and Pavitt, G. D. (2000) Mol. Cell. Biol. 20, 3965-3976[Abstract/Free Full Text]
21. Hannig, E. M., and Hinnebusch, A. G. (1988) Mol. Cell. Biol. 8, 4808-4820[Medline] [Order article via Infotrieve]
22. Kimball, S. R., Fabian, J. R., Pavitt, G. D., Hinnebusch, A. G., and Jefferson, L. S. (1998) J. Biol. Chem. 273, 12841-12845[Abstract/Free Full Text]
23. Craddock, B. L., and Proud, C. G. (1996) Biochem. Biophys. Res. Commun. 220, 843-847[CrossRef][Medline] [Order article via Infotrieve]
24. Rowlands, A. G., Panniers, R., and Henshaw, E. C. (1988) J. Biol. Chem. 263, 5526-5533[Abstract/Free Full Text]
25. Hwang, Y. W., and Miller, D. L. (1985) J. Biol. Chem. 260, 11498-11502[Abstract/Free Full Text]
26. Klebe, C., Bischoff, F. R., Ponstingl, H., and Wittinghofer, A. (1995) Biochemistry 34, 639-647[Medline] [Order article via Infotrieve]
27. Klebe, C., Prinz, H., Wittinghofer, A., and Goody, R. S. (1995) Biochemistry 34, 12543-12552[Medline] [Order article via Infotrieve]
28. Lenzen, C., Cool, R. H., Prinz, H., Kuhlmann, J., and Wittinghofer, A. (1998) Biochemistry 37, 7420-7430[CrossRef][Medline] [Order article via Infotrieve]
29. Hutchinson, J. P., and Eccleston, J. F. (2000) Biochemistry 39, 11348-11359[CrossRef][Medline] [Order article via Infotrieve]
30. Dholakia, J. N., and Wahba, A. J. (1989) J. Biol. Chem. 264, 546-550[Abstract/Free Full Text]
31. Nika, J., Yang, W., Pavitt, G. D., Hinnebusch, A. G., and Hannig, E. M. (2000) J. Biol. Chem. 275, 26011-26017[Abstract/Free Full Text]
32. Dholakia, J. N., Francis, B. R., Haley, B. E., and Wahba, A. J. (1989) J. Biol. Chem. 264, 20638-20642[Abstract/Free Full Text]
33. Bommer, U. A., Salimans, M. M., Kurzchalia, T. V., Voorma, H. O., and Karpova, G. G. (1988) Biochem. Int. 16, 549-557[Medline] [Order article via Infotrieve]
34. Bommer, U. A., and Kurzchalia, T. V. (1989) FEBS Lett. 244, 323-327[CrossRef][Medline] [Order article via Infotrieve]
35. Hannig, E. M., Cigan, A. M., Freeman, B. A., and Kinzy, T. G. (1993) Mol. Cell. Biol. 13, 506-520[Abstract]
36. Gaspar, N. J., Kinzy, T. G., Scherer, B. J., Humbelin, M., Hershey, J. W., and Merrick, W. C. (1994) J. Biol. Chem. 269, 3415-3422[Abstract/Free Full Text]
37. Cherfils, J., and Chardin, P. (1999) Trends Biochem. Sci. 24, 306-311[CrossRef][Medline] [Order article via Infotrieve]
38. Sprang, S. R., and Coleman, D. E. (1998) Cell 95, 155-158[Medline] [Order article via Infotrieve]
39. Price, N. T., and Proud, C. G. (1994) Biochimie (Paris) 76, 748-760[CrossRef][Medline] [Order article via Infotrieve]
40. Dever, T. E., Chen, J. J., Barber, G. N., Cigan, A. M., Feng, L., Donahue, T. F., London, I. M., Katze, M. G., and Hinnebusch, A. G. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 4616-4620[Abstract]
41. Dever, T. E., Feng, L., Wek, R. C., Cigan, A. M., Donahue, T. F., and Hinnebusch, A. G. (1992) Cell 68, 585-596[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.